Generic Name and Formulations:
Vilazodone HCl 10mg, 20mg, 40mg; tabs.
Indications for VIIBRYD:
Major depressive disorder.
Take with food. Initially 10mg once daily for 7 days, then 20mg once daily for 7 days, then increase to 40mg once daily. Concomitant strong CYP3A4 inhibitors: max 20mg once daily. Concomitant strong CYP3A4 inducers for >14 days: consider increasing dose up to 2-fold over 1–2 weeks; max 80mg daily. Readjust to original level when CYP3A4 inhibitors or inducers (in 14 days) are discontinued.
During or within 14 days of MAOIs; do not start an MAOI during or within 14 days of vilazodone. Concomitant linezolid or IV methylene blue.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults; monitor for clinical worsening or unusual changes. Screen for bipolar disorder. Monitor for serotonin syndrome; discontinue if occurs. Increased risk of bleeding. History of mania/hypomania. Seizure disorder. Angle-closure glaucoma. Volume depleted. Avoid abrupt disruption. Reevaluate periodically. Write ℞ for smallest practical amount. Elderly. Pregnancy; effects on neonate exposed in 3rd trimester (see full labeling). Nursing mothers.
See Contraindications. Avoid alcohol. Increased risk of serotonin syndrome with other serotonergic drugs (eg, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, St. John's Wort) or with drugs that impair serotonin metabolism (eg, MAOIs, linezolid, IV methylene blue). Increased risk of bleeding with concomitant aspirin, NSAIDs, warfarin (monitor), other anticoagulants. Potentiated by strong CYP3A4 inhibitors (eg, itraconazole, clarithromycin, voriconazole); see Adult. Antagonized by strong CYP3A4 inducers (eg, carbamazepine, phenytoin, rifampin); see Adult. Monitor digoxin. Caution with other highly protein-bound drugs.
Selective serotonin reuptake inhibitor + 5-HT1A receptor partial agonist.
Diarrhea, nausea, vomiting, insomnia; hyponatremia/SIADH (esp. in elderly).
Tabs—30; Patient Starter Kit (7x10mg tabs + 7x20mg tabs + 16x40mg tabs; 7x10mg tabs + 23x20mg tabs)—30
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|